Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Brompheniramine maleate
Brompheniramine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Brompheniramine maleate | EXPERIMENTAL | Brompheniramine maleate oral solution 1 mg/5 mL, single dose |
| Name | Type | Description |
|---|---|---|
| Brompheniramine maleate | DRUG | - |
Inclusion Criteria: 1. Males or females between 2 to less than 18 yrs of age with a minimum weight of 24 pounds and within the 5th and 95th percentiles in height and weight, and BMI based on age and gender 2. Symptomatic or asymptomatic children/adolescents as follows: * A prior diagnosis of al...
Brompheniramine is used for allergic reactions. It is an antihistamine small molecule being studied in a Phase 1 clinical program, with one completed trial in children and adolescents aged 2 years and older. It is not described as approved for marketing in this program.
Brompheniramine targets HRH1, the histamine H1 receptor, acting as an antagonist. By blocking HRH1, it interferes with histamine signaling that drives allergic responses, which is the basis for its use in allergic reactions.
Brompheniramine is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the sponsor associated with the clinical development program for this antihistamine asset in allergic reactions.
Brompheniramine is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are ongoing. The program remains investigational and has not been described as approved for the allergic reactions indication.
Brompheniramine has been studied in one completed Phase 1 trial, NCT00894634, titled Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents. It enrolled 37 participants aged 2 years and older, was uncontrolled, and was not randomized or double blinded.
Yes, Brompheniramine maleate is an alternative name for Brompheniramine. The maleate refers to the salt form used in the clinical program, including the completed Phase 1 trial NCT00894634 that evaluated the liquid formulation in children and adolescents.